Skip to content
Review

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

Oct 2026 · Lancet Neurology · Vol 25 10, pp. 952-964 · 1 citation · 58 references
Medicine

TL;DR

If anti-amyloid therapies prove beneficial for cognitively unimpaired people with ADNC and become part of routine practice, several key knowledge gaps must be addressed to support safe, scalable, real-world implementation of Alzheimer's disease treatment.

Abstract

The recent approval of disease-modifying therapies for symptomatic Alzheimer's disease is a major advance for a condition with few therapeutic options. Anti-amyloid monoclonal antibodies have shown clinically meaningful benefits in slowing cognitive decline. Clinical trials in symptomatic Alzheimer's disease suggest that anti-amyloid therapies might provide the greatest benefit in subgroups who have low baseline levels of Alzheimer's disease pathology; ongoing prevention trials are evaluating these therapies in cognitively unimpaired individuals who have biomarker evidence of Alzheimer's disease neuropathological change (ADNC). However, the possibility of biomarker testing and treatment in cognitively unimpaired people raises key questions about ethics and the consequences that follow from a positive test or an uncertain result (ie, the so-called downstream effects on patients and health systems). Furthermore, test accuracy might be questioned when ADNC has a low prevalence in the population being tested and in the case of intermediate-range biomarker concentrations that might not reliably indicate true ADNC or be false positives. If anti-amyloid therapies prove beneficial for cognitively unimpaired people with ADNC and become part of routine practice, several key knowledge gaps must be addressed to support safe, scalable, real-world implementation of Alzheimer's disease treatment.

View source

Similar papers

Review

Alzheimer’s Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations

This comprehensive review synthesizes current knowledge across the full spectrum of AD, encompassing molecular pathophysiology (amyloid cascade, tau hyperphosphorylation, and neuroinflammation), genetic architecture, genetic architecture (familial mutations and APOE-mediated risk), evolving biomarker-based diagnostic f...

Azzam Zrineh, Rami Akwan, Roaa Darawsheh et al. · 0 citations
Open access Oct 2026

Comparing criteria for objective cognitive staging in preclinical Alzheimer's disease

Abstract INTRODUCTION Individuals with preclinical Alzheimer's disease may develop objective subtle cognitive decline (OSCD) as they transition between the cognitively unimpaired and mild cognitive impairment stages. Selection of individuals with OSCD into clinical trials may provide enrichment for participants likely...

Kelsey K. Amon, Chao Huang, Holly H. Fleischmann et al. · 0 citations
Review Open access Oct 2026

Disease-modifying therapies in Alzheimer's disease: anti-amyloid monoclonal antibodies and clinical perspectives

Background: Alzheimer's disease is characterized by progressive cognitive decline and the accumulation of beta-amyloid and neurofibrillary tangles in the brain. Traditionally, treatments have only been symptomatic, but anti-amyloid monoclonal antibodies, such as lecanemab and donanemab, are emerging as therapies capabl...

Isabella Motta Melo, Isadora Silveira Ralin, M. Corcinio · 0 citations
Open access Oct 2026

Statistical efficiency of outcome measures for secondary prevention trials in Alzheimer's disease: Evidence from the A4 trial

Abstract INTRODUCTION Secondary prevention trials targeting preclinical Alzheimer's disease (AD) require clinical outcome assessments (COAs) that are sensitive to subtle decline that might be found in the cognitively unimpaired population typically enrolled in these trials. The recently completed Anti‐Amyloid Treatment...

Jasmin A. Duehring, Howard H. Feldman, D. Salmon et al. · 0 citations
Open access Oct 2026

Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer’s disease

Alzheimer’s disease (AD) pathology accumulates years before overt cognitive impairment, yet its multidomain phenotype remains poorly defined. To limit confounding by uncontrolled comorbidities, we assembled a cohort of 644 older adults self-reporting intact cognition, free of systemic or neurological diseases and manag...

Liat Tsoran, Yuval Rom, Ahlam Taha et al. · 0 citations
Review Open access Sep 2026

Understanding Alzheimer's disease through biomarkers: pathology, progression, and clinical application.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...

Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.